Loading company…
Vironexis develops AAV-delivered T-cell immuno-gene therapies for cancer.
Founded in 2021, Vironexis Biotherapeutics develops AAV-delivered T-cell immuno-gene therapies for blood cancers and solid tumors. Its TransJoin™ platform is designed to deliver engineered transgenes to T cells through a one-time infusion. In October 2022, the company raised USD 26 mn in seed funding led by Drive Capital and Future Ventures to advance oncology programs toward clinical trials.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in